

IMI 2 – Call 2: EBOLA+ programme Rules and procedures


Fabrizio Federici • IMI Legal Officer
Catherine Brett • IMI External Relations Manager

Outline

- Introducing the single stage, fast-track process
- Participation & funding rules
- How to apply
- More information

Introducing the single stage, fast-track procedure

Single stage, fast-track process



Single stage, fast-track process

- **'Single stage'**

Call for full proposals combining private and public partners

- **'Fast-track'**

Due to the urgent nature of the Ebola outbreak, reduced time for Call publication, proposals submission / evaluation, and granting

- All proposals competing across 5 topics, **one single ranking list**

- **Timeline**

Call published: **6 November**

Submission deadline: **1 December**

Evaluation, award and granting: expected by **end 2014**

Keeping the momentum – Grant Agreement & Consortium Agreement

In theory

Indicative maximum Time To Grant: **3 months** from Full Proposal submission deadline

(2 months to inform applicants of outcome of evaluation + 1 month for signature of GA)

Validation of legal entities (PIC) to be run in parallel (12/2014)

In practice

Due to **urgent nature** of Ebola outbreak, **GAs** expected to be **signed by end 2014** and **projects to start asap** (January 2015)

Consortium Agreement to be **signed within 6 months** of the start of the project

Participation & funding rules

Conditions for participation

- **H2020 Rules for participation** apply to IMI Call for proposals and Actions except where specifically derogated
- **Admissibility and Eligibility** criteria as explained in **IMI2 Call documents**
- **Minimum condition** – each consortium shall include at least **three independent legal entities**, each established in a **different EU Member State** or **H2020 associated country**
(3rd countries do not count!)

Who can participate?

Any legal entity carrying out work relevant to the Call objectives may participate in applicant consortia, regardless of its place of establishment.

Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (\leq €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- **EU Member State**
- **Associated Country**
- **third country**
(Annex A, H2020 General WP 2014/15)

Other countries:
No funding unless participation deemed essential by IMI for carrying out the action

Expected consortia

- **Public/private consortia consisting of:**
 - industry companies (in-kind and direct financial contributions)
 - IMI fundable legal entities carrying out activities relevant for achieving the project objectives
 - additional legal entities carrying out activities relevant for achieving the project objectives.

IMI 2 – one single funding rate

One single funding rate per project

- for **all beneficiaries** receiving IMI 2 funding
- for **all types of activities**

Funding rates

- **100%** of **direct** eligible costs
- **25%** **indirect** costs - flat rate

EFPIA contribution

- **EFPIA companies**

- In-kind (actual direct and indirect costs or average FTE) + cash contributions
- Based on the usual management principles and accounting practices
- Contributions from affiliated entities as part of in-kind

To meet the specific Call objectives, a significant part of the EFPIA contribution is expected to be from non-EU countries

Reference documents

- Call text and other Call documents (incl. FAQs)
- H2020 Rules for Participation
- IMI2 Delegated Regulation
- Annexes A, B and C of the H2020 Work Programme 2014-2015
- IMI2 JU Manual for submission, evaluation, and grant award
- IMI2 model Grant Agreement
- IMI2 annotated Grant Agreement (soon)

www.imi.europa.eu/content/imi-2-call-2-0



How to apply

Submitting a proposal

- Full Proposals **must** be submitted via **SOFIA** – **sofia.imi.europa.eu**
 - *No other means of submission will be accepted*
- To **access SOFIA**, Applicant Consortium Coordinators will need to complete a **Request for Access**
- SOFIA will **open** for submission of proposals on **22 November**
 - *Before then, use the **proposal templates for guidance***
- You can **update your proposal** online before the submission deadline
- Don't forget to **press the submit button!**
- SOFIA will **close** on **1 December** at **17:00 CET**

Finding partners

- Via the IMI Partner Search Tool - <http://www.imi.europa.eu/content/partner-search>



imi | innovative medicines initiative

Partner Search Tool

My Data

Partner Search

Current User:

[Log out](#)


Partner Search PST PARTICIPANT SEARCH

You can combine any search criteria from the list of the below partner characteristics.

- ▶ Partner characteristics...
- ▶ EBOLA - Topic 1: Vaccine development Phase I, II, and III...
- ▶ EBOLA - Topic 2: Manufacturing capability...
- ▶ EBOLA - Topic 3: Stability of vaccines during transport and storage...
- ▶ EBOLA - Topic 4: Deployment and compliance of vaccination regimens...
- ▶ EBOLA - Topic 5: Rapid diagnostic tests...
- ▶ Remote Assessment of Disease and Disease CNS

Finding partners

- Via the IMI LinkedIn group – <http://www.linkedin.com/groups/Innovative-Medicines-Initiative-1126077>



The screenshot shows the LinkedIn interface for the 'Innovative Medicines Initiative' group. At the top, there is a search bar and navigation links for Home, Profile, Connections, Jobs, and Interests. Below the group name, there are tabs for Discussions, Members, Search, and Manage. The main content area features a post by Theo Meert, a Manager's Choice, with a profile picture and a message: 'Dear all if anyone likes to contact a JnJ person for any of the topics for the Ebola+ program, drop me an email at tmeert@its.jnj.com or...'. Below this is a 'Start a discussion or share something with the group...' input field. Further down, there is a post by Catherine Brett, a Top Contributor, titled 'New on our website today - FAQs on the Ebola+ programme'. The post includes links to FAQs and information about webinars and financial contributions.

Top tips for applicants

- **Read and understand the Call documents**
- If something is unclear, **contact us**
- Make sure your proposal addresses **all the objectives of the topic**, and that your consortium includes **all the expertise** needed
- Ensure your proposal includes all the information the **evaluators** will need to assess it. (The evaluation form is online...)
- Don't forget to address any **ethical issues**
- Ensure your proposal meets the **basic requirements** for the Call. I.e. make sure you **submit on time**, in the correct **format**, and that your consortium respects the basic **eligibility criteria** (e.g. number and location of partners).



More information

Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu



- Home
- About IMI
- Ongoing projects
- Calls for proposals
- News, Events & Media
- Reference documents

- PARTNER SEARCH
- EDUCATION & TRAINING
- SMALL & MEDIUM-SIZED ENTERPRISES
- INTELLECTUAL PROPERTY

THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

IMI LAUNCHES EBOLA+ PROGRAMME
IMI has launched an ambitious programme to accelerate the development of **vaccines and treatments against Ebola and related diseases**. The first Call under the Ebola+ programme has a total budget of €280m.

IMI NEWSFLASH
10/11/2014 : Got questions about IMI's #Ebola programme? Check the FAQs and sign up to our webinars on 12/11 and 17/11 <http://t.co/gaZFnWZk1a>
06/11/2014 : IMI #Ebola Topic 5: rapid #diagnostic tests that work in the real world <http://t.co/gaZFnWZk1a>
06/11/2014 : IMI #Ebola Topic 4: using technology to promote #vaccine compliance <http://t.co/gaZFnWZk1a>

NEWSLETTER
[Read & subscribe](#) [more](#)

AGENDA

- 03/12/2014 - C-Path and IMI 2nd Annual Meet...
- 26/11/2014 - Bringing health-related life s...
- 18 - 18/11/2014 - Financial Management Workshop ...



Your contact points

- Contact the **IMI Programme Office**
infodesk@imi.europa.eu
- Get in touch with your **local IMI contact point**
www.imi.europa.eu/content/states-representatives-groups
- Talk to your **Health National Contact Point (NCP)**
http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html

Thank you

IMI Programme Office
infodesk@imi.europa.eu

www.imi.europa.eu

 @IMI_JU